"A new class of anti-obesity drugs that suppresses appetite by blocking cannabinoid receptors in the brain could also suppress the adaptive rewiring of the brain necessary for neural development in children, studies with mice have indicated. One such drug, rimonabant (trade name Acomplia) has been developed by Sanofi-Aventis and is awaiting approval for use in the U.S., and other pharmaceutical companies are developing similar drugs."As if they should not always use "caution" with any drug and for anyone.
Fitness Watch is your site for making sense of fitness advice.
"Truth" has a shelf life.
The shelf life of "truth" is very short in the domains of fitness, health and well-being.
The reason is that so much of what we are told is "true" is really baseless.
At Fitness Watch we separate fitness information from fitness noise.
Saturday, May 17, 2008
Caution Recommended For New Anti-Obesity Drug In Children
Oops.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.